A deep dive on weight loss from Ozempic & other GLP-1 agonist drugs

up_statuss

Join us as Professor Rachel Brown provides a deep dive on the highly sought after weight loss drugs. So sought after, that there are shortages of these drugs across the globe.

We cover:

• What is GLP-1?
• How is GLP-1 different in obese individuals?
• What are glucagon-like peptide (GLP-1) agonists?
• What are some known brands that people may have heard about? Where are these available?
• How long have these injections been around for?
• What are clinical trials showing when it comes to this medication and weight loss?
• Some people do not see weight loss on these drugs, why may this be?
• How do people describe their experience on the drug?
• With the absence of long-term safety data, what is the current recommendation for when individuals should come off the drug?
• What have clinical trials shown once participants stop taking the drug?
• It’s important for people to get an understanding of the different aspects that meals play in impacting GLP-1. What are some key aspects for our listeners?
• Why should someone seriously consider working with a nutritionist alongside taking this drug?
• What does the future of weight loss look like 10, 20, 30 years from now?

One-liners you don’t want to miss:

“It wasn’t until 2014 that we saw that one of the GLP-1 drugs was approved for people with obesity in the US. It didn’t capture the public’s attention so much as there was some wight loss but probably not as large as what we are seeing today.”

“It is quite impressive the weight loss that we are seeing. The Mounjaro (tirzepatide) actually has the highest weight loss that we have seen in clinical trials, up to around 22% of body weight is lost in people without diabetes and about 15% for people living with diabetes.”